Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Shuttle Pharmaceuticals Holdings Inc

SHPH ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: N/A

Last Close

$4.61

▼ -4.36%

Market Cap $21.97M · Vol 865

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$21.97M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

55.47

Momentum

Beta

1.16

vs Market

52W High

$44.00

89.05% below

52W Low

$2.62

83.97% above

Volume

865

Avg 5.71K

P/B

1.62

Price-to-book

ROE

N/A

Return on equity

Free Float

99.16%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Shuttle Pharmaceuticals Holdings Inc (SHPH) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does SHPH pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-17.24%

+22.61%

+50.65%

-48.78%

YTD

-74.39%

-85.68%

-99.60%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-11,721,670.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-180.58% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	1.62
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	4.76M

Technical Indicators

50-Day SMA	$4.05
200-Day SMA	$7.41
RSI (14)	55.47
Beta	1.16
52-Week High	$44.00
52-Week Low	$2.62

Volume Today	865
Avg Daily Volume (30D)	5.71K
Relative Volume	0.15x
Volatility (10D)	76.36
Volatility (30D)	106.67
Free Float	99.16%

Analyst Consensus

N/A

Current Price $4.61

Mean Target N/A

52W Low$2.62 52W High$44.00

Current

Target

$2.62 $44.00

Current Analyst target

· 0 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG017Z2NGC6

ISINUS8256935003

CountryUSA

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG +0.74% ONC BeOne Medicines AG -1.08% 068270.KS Celltrion, Inc. -1.67% MEDP Medpace Holdings, Inc. -1.29% CRL Charles River Laboratories International, Inc. -1.51%

Company Profile

Shuttle Pharmaceuticals Holdings, Inc. is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Its product candidates include Ropidoxuridine, a Phase II, clinical-stage radiation sensitizer, a platform of HDAC inhibitors (SP-1-161, SP-2-225 and SP-1-303), and two preclinical, prostate cancer-oriented diagnostics assets: PC-RAD Test, a blood test to predict clinical response to radiation therapy and PSMA-B ligand for potential use as a theranostic agent. Ropidoxuridine (IPdR) is for use in combination with RT to treat brain tumors (glioblastoma) and sarcomas. SP-1-161 is a candidate lead of compounds demonstrating activation of the ATM gene product (mutated in Ataxia-Telangiectasia). SP-2-225 is a candidate lead of compounds demonstrating Class II (HDAC6) selective inhibition. SP-1-303 is a candidate Class I HDAC inhibitor with preferential efficacy against ER positive cancers.